CD84 and infection: Unlike broad immunosuppressive strategies such as alemtuzumab, which deplete both T and B cells and carry risks of infection and secondary autoimmunity SLAMF5 blockade selectively modulates CNS myeloid cell activity and may preserve peripheral immune function, offering a more targeted therapeutic approach.